Long-term Outcomes After Bladder-preserving Tri-modality Therapy for Patients with Muscle-invasive Bladder Cancer: An Updated Analysis of the Massachusetts General Hospital Experience-Reference-Cited by-同舟云学术

Long-term Outcomes After Bladder-preserving Tri-modality Therapy for Patients with Muscle-invasive Bladder Cancer: An Updated Analysis of the Massachusetts General Hospital Experience

Published:2017-06 Issue:6 Volume:71 Page:952-960
ISSN:0302-2838
Container-title:European Urology
language:en
Short-container-title:European Urology

Author:

Giacalone Nicholas J.,Shipley William U.,Clayman Rebecca H.,Niemierko Andrzej,Drumm Michael,Heney Niall M.,Michaelson Marc D.,Lee Richard J.,Saylor Philip J.,Wszolek Matthew F.,Feldman Adam S.,Dahl Douglas M.,Zietman Anthony L.,Efstathiou Jason A.

Publisher

Elsevier BV

Subject

Urology

Reference36 articles.

1. Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer;Grossman;N Engl J Med,2003

2. Neoadjuvant cisplatinum based combination chemotherapy in patients with invasive bladder cancer: a combined analysis of two Nordic studies;Sherif;Eur Urol,2004

3. Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1054 patients;Stein;J Clin Oncol,2001

4. Super extended versus extended pelvic lymph node dissection in patients undergoing radical cystectomy for bladder cancer: a comparative study;Zehnder;J Urol,2011

5. Defining early morbidity of radical cystectomy for patients with bladder cancer using a standardized reporting methodology;Shabsigh;Eur Urol,2009

Cited by 281 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Bladder sparing options for muscle-invasive bladder cancer;Current Opinion in Urology;2024-09-03

2. Bladder-Preserving Trimodality Treatment for High-Grade T1 Bladder Cancer: Results From Phase II Protocol NRG Oncology/RTOG 0926;Journal of Clinical Oncology;2024-09-03

3. Radical cystectomy versus trimodal therapy for muscle-invasive bladder cancer: Analysis of an other-cause mortality matched cohort;Urologic Oncology: Seminars and Original Investigations;2024-09

4. Patient-derived Organoids in Bladder Cancer: Opportunities and Challenges;European Urology Focus;2024-09

5. Short-term Outcome of RPVBT Combined with Chemotherapy for Patients with Single, < 3 cm, T2 Stage Bladder cancer;Biological Procedures Online;2024-08-20